Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · June 27, 2023

Atezolizumab Plus Cabozantinib vs Cabozantinib Monotherapy for Renal Cell Carcinoma After Progression on Previous ICI Treatment

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Lancet 2023 Jun 02;[EPub Ahead of Print], SK Pal, L Albiges, P Tomczak, C Suárez, MH Voss, G de Velasco, J Chahoud, A Mochalova, G Procopio, H Mahammedi, F Zengerling, C Kim, T Osawa, M Angel, S Gupta, O Khan, G Bergthold, B Liu, M Kalaitzidou, M Huseni, C Scheffold, T Powles, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading